#USA #Actinium-225 #Burlington, Massachusetts #NorthStar Medical #QSA Global

NorthStar and QSA Global's Strategic Partnership for Actinium-225

In a significant development for targeted alpha therapies (TAT), NorthStar Medical Radioisotopes, LLC, and QSA Global, Inc. have announced a long-term strategic alliance. This partnership is set to enhance the supply chain for Actinium-225 (Ac-225), a crucial element in the fight against cancer through innovative therapies. The collaboration combines NorthStar's robust radioisotope production capabilities with QSA Global's extensive experience in managing the lifecycle of Radium-226 (Ra-226), the precursor needed for Ac-225 production.

Goals of the Partnership

The primary goal of this alliance is to establish a reliable, closed-loop supply chain for high-purity Ra-226 materials, which will be crucial for the commercial production of non-carrier-added Actinium-225 (n.c.a. Ac-225). By ensuring a steady supply of essential materials, NorthStar can confidently meet the rising demand within the industry for cancer therapies that utilize Ac-225.

Dr. Frank Scholz, President and CEO of NorthStar, highlighted that this multi-year agreement fortifies their supply chain with dependable, high-quality Ra-226 targets vital for producing n.c.a. Ac-225. This infusion of reliable materials will empower NorthStar to address the growing needs of the healthcare sector.

On the other hand, QSA Global will leverage its decades of specialized knowledge in handling high-activity sources and regulatory compliance. Dr. Joe Lapinskas, Innovation Director at QSA Global, noted that their expertise will free partners like NorthStar to focus solely on the commercial production of Ac-225. QSA Global has committed to processing the residual Ra-226 on behalf of NorthStar, converting it into high-purity precursors that will continuously feed into the manufacturing of target capsules.

The Role of Actinium-225 in Modern Medicine

Ac-225 is a promising radioisotope that emits alpha radiation, proficiently targeting diseased cells while minimizing damage to surrounding healthy tissue. This characteristic makes it particularly valuable for developing highly effective targeted radiotherapies. The flexibility of Ac-225 allows it to bind to various targeting molecules, including antibodies and peptides, facilitating precise delivery to cancer cells.

The collaboration is further solidified with QSA Global committing to recycling the recovered radium back into new targets, thus promoting a highly efficient, closed-loop supply chain.

About the Partners

NorthStar Medical Radioisotopes

NorthStar has pioneered the commercial production of n.c.a. Ac-225 through an indirect manufacturing method that combines electron beam irradiation of a Ra-226 target with purified Ra-225 sources. Their commitment to innovative technologies positions them at the forefront of radioisotope pharmaceuticals, playing a vital role in cancer diagnosis and treatment.

QSA Global, Inc.

QSA Global stands as a leader in the manufacturing of high-performance radiation sources and supporting medical radiochemical services. With a strong foundation in industrial radioisotopes, QSA is expanding its capabilities to cater to the rapidly growing medical radioisotope market and TAT applications. Their state-of-the-art facilities are equipped for radio-chemical processing, purification, and regulatory compliance, ensuring the integrity of the supply chain.

Conclusion

The alliance between NorthStar and QSA Global signifies a critical step forward in biomedical innovations. By enhancing the supply chain for Actinium-225, this partnership will not only streamline production processes but also bolster the capacity for developing next-generation cancer treatments. As the demand for targeted alpha therapies continues to grow, collaborative efforts like these pave the way for more effective and life-saving medical solutions in the future.